Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.

Panje, Cédric; Hayoz, Stefanie; Eisterer, Wolfgang; Hess, Viviane; Thuss-Patience, Peter; Schacher, Sabina; Dürr, Donat; Wagner, Anna Dorothea; Girschikofsky, Michael; Eboulet, Eric; Stahl, Michael; Ruhstaller, Thomas (2022). Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. European journal of cancer, 177, pp. 186-193. Elsevier 10.1016/j.ejca.2022.09.035

[img] Text
1-s2.0-S0959804922007754-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (377kB) | Request a copy


Recurrent oesophageal cancer after the initial curative multimodality treatment is a disease condition with a poor prognosis. There is limited evidence on recurrence patterns and on the optimal therapeutic approach.


We analysed the pattern of disease recurrence and subsequent therapies in patients with recurrent oesophageal cancer based on prospectively collected data within a predefined subproject of the randomised phase 3 trial Swiss Group for Clinical Cancer Research (SAKK) 75/08.


Among 300 patients included in the SAKK 75/08 trial, tumour recurrence was observed in 103 patients with a median follow-up of 5.8 years. Locoregional recurrence only was found in 26.2% of the patients, 21.4% of patients had both distant and locoregional recurrence and 52.4% of patients had distant recurrence only. Fifty-nine patients (58%) received at least one line of systemic therapy at recurrence, most commonly oxaliplatin-based combination therapies for adenocarcinoma and single-agent chemotherapy for squamous cell carcinoma. Local therapies, most commonly palliative radiotherapy, were used in 49 patients (48%). Six patients underwent a second curative resection or radiochemotherapy. We found no significant overall survival difference for isolated locoregional recurrence versus distant recurrence (15.1 versus 8.7 months, p = 0.167). In a multivariable Cox regression model, time from oesophagectomy to recurrence and the number of recurrence sites as well as the use of systemic therapy or a second curative local therapy significantly correlated with overall survival.


Recurrent oesophageal cancer remains a disease with a poor prognosis and requires multidisciplinary management. A second curative approach for localised disease recurrence may be an option for highly selected patients.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Panje, Cédric


600 Technology > 610 Medicine & health








Pubmed Import

Date Deposited:

17 Nov 2022 14:01

Last Modified:

05 Dec 2022 16:28

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Chemotherapy Oesophageal cancer Radiotherapy Recurrence Trimodality




Actions (login required)

Edit item Edit item
Provide Feedback